Cost-Effectiveness of Lidocaine Medicated Patch Compared with Pregabalin and Gabapentin for the Treatment of Postherpetic Neuralgia an Diabetic Polyneuropathy in Colombia

Abstract

0 1 7 ) A 8 5 3 -A 9 4 3 A867 generated a tornado diagram, and a two-way deterministic one considering the two key parameters that differentiate CRRT from IRRT: the daily implementation cost difference and the cumulative risk of dialysis dependence. We used the threshold of 3 times per capita GDP, that is, R $ 84,741 (3 X R $ 28,247) as the threshold for cost-effectiveness. Results: CRRT is dominant vs. IRRT from 18 months of treatment. Based our assumptions, the cohort of patients initially treated with CRRT had better clinical outcomes QALY´s and lower total costs of treatment. Patients treated with CRRT are more likely to recover renal function. ConClusions: CRRT when compared to IRRT can be considered a dominant therapy, that is, it offers better outcomes and lower total treatment costs, under the perspective of the private healthcare system in Brazil. objeCtives:The aim of this study is to identify the cost-effectiveness of International Normalized Ratio (INR) monitoring in patients with coagulation disorders by comparing portable coagulometers with conventional hospital care in the Mexican context. Methods: A Markov model was developed with 3 health states: no event, permanent disability and death; with 100 patients in the cohort. In addition, the following complications were considered: major bleeding, minor hemorrhage, thrombotic event and temporal disability. Costs within the Mexican Health Care System were estimated for each health status and the cost-effectiveness ratio between hospital and portable coagulometers in a hospital setting, considering a 10-year time horizon. Main Outcomes: Years of Life gained; Total costs; Incremental Cost-Effectiveness Ratio (ICER); And Avoided Events. Results: The most effective treatment alternative were portable coagulometers reporting 6,998 years of life gained, which is 2% higher than the result obtained with hospital care; In addition, it was the least costly alternative with $ 8,811 USD per patient, which is 20% lower than the total cost calculated for hospital care. Therefore, portable coagulometers approach is a dominant alternative compared to hospital care; it has potential savings of $ 2,309 USD and it reports an incremental effectiveness of 0.1135 years of life gained per patient. ConClusions: The results of the present economic study show that using portable coagulometers in a hospital environment is a cost-saving alternative for the care of patients with long-term oral anticoagulation treatment (Warfarin). This is due to the fact that portable coagulometers, compared with hospital care, significantly reduces the costs of monitoring, thrombotic events and disability; While 6 minor hemorrhages and 12 thrombotic events are avoided per cohort. Therefore, it is possible to conclude that the present study identified portable coagulometers as the dominant alternative for the monitoring of INR in patients under oral anticoagulation therapy.

Economic burden of herpes zoster in Latin America: A systematic review and meta-analysis

“…The 23 studies reported data for Brazil (n = 7), 53–58 – 65 Argentina (n = 5), 47 , 48 - 50–52 , Colombia (n = 4), 59–61 – 64 Mexico (n = 3), 63 , 66 , 68 Costa Rica (n = 1), 62 Nicaragua (n = 1), 69 and Latin America [including Brazil, Mexico and Argentina] (n = 1) 49 whereas one multi-regional study provided aggregate results for Latin America (n = 1), 67 with the same countries included ( Table 1 ).…”

“…Table 1 provides an overview of cost per patient data. Studies reported different perspectives when estimating costs such as social perspective (n = 3), 49 , 59 , 60 third-party payer perspective (n = 1) 64 and the public perspective (n = 1). 65 Out-of-pocket expenses were reported in two studies.…”